^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    1d
    Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus (clinicaltrials.gov)
    P4, N=64, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed
    Trial completion
    1d
    Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (clinicaltrials.gov)
    P1, N=20, Completed, Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting --> Completed | Trial completion date: May 2025 --> Jan 2025
    Trial completion • Trial completion date
    6d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    8d
    A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 (clinicaltrials.gov)
    P2, N=50, Completed, Chiesi Farmaceutici S.p.A. | Recruiting --> Completed
    Trial completion
    16d
    Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. (PubMed, Diabetes Metab Syndr Obes)
    Roflumilast may offer superior glycemic and oxidative stress control benefits, though neuropathy symptoms control was comparable to ALA. (NCT05369793).
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Daliresp (roflumilast)
    17d
    A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov)
    P3, N=51, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    Phase I study on the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose administration in healthy subjects and multiple-dose administration in COPD patients of HRS-9821 inhalation powder aerosol (ChiCTR2500107601)
    P1, N=82, Not yet recruiting, West China Hospital of Sichuan University; Guangdong Hengrui Medicine Co., Ltd.
    New P1 trial
    1m
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Verona Pharma plc | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (clinicaltrials.gov)
    P3, N=3973, Active, not recruiting, Chiesi Farmaceutici S.p.A. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Dec 2025 | Trial primary completion date: Apr 2027 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Daliresp (roflumilast)
    2ms
    Mulberry (Morus alba l.) leaf improves arachidonic acid metabolism disorder in chronic obstructive pulmonary disease. (PubMed, Phytomedicine)
    ARA metabolic dysregulation contributes to COPD pathogenesis, and (±)12-HETE, 15(S)-HETE, and (±)11-HETE may serve as potential biomarkers for COPD. MLWE exert therapeutic effects by modulating ARA metabolism, ameliorating oxidative stress, and suppressing inflammatory responses, offering a novel strategy for COPD prevention and treatment.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • LOX (Lysyl Oxidase) • IL1B (Interleukin 1, beta) • ALOX15 (Arachidonate 15-Lipoxygenase) • CAT (Catalase)
    2ms
    Prevention of Cisplatin-induced Nephrotoxicity (clinicaltrials.gov)
    P2/3, N=24, Not yet recruiting, Mahidol University | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin
    2ms
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Verona Pharma plc | Not yet recruiting --> Recruiting
    Enrollment open